Literature DB >> 7577480

Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer.

D J Kerr1, G J Rustin, S B Kaye, P Selby, N M Bleehen, P Harper, M H Brampton.   

Abstract

Rhizoxin is a tubulin-binding anti-neoplastic agent which is active in a range of murine tumour models. The recommended schedule, of intravenous (i.v.) bolus administration at a dose of 2 mg m-2 every 3 weeks, has been assessed in three phase II trials of ovarian, renal and colorectal cancer. In general terms the drug was fairly well tolerated, but the response rate was disappointing: 0/18, colorectal cancer; 0/18, renal cancer; 1 partial response (PR)/17, ovarian cancer.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7577480      PMCID： PMC2033922          DOI： 10.1038/bjc.1995.498

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  4 in total

1.  Phase I and pharmacokinetic study of rhizoxin.

Authors:  D Bissett; M A Graham; A Setanoians; G A Chadwick; P Wilson; I Koier; R Henrar; G Schwartsmann; J Cassidy; S B Kaye
Journal:  Cancer Res       Date:  1992-05-15       Impact factor: 12.701

2.  Rhizoxin binding to tubulin at the maytansine-binding site.

Authors:  M Takahashi; S Iwasaki; H Kobayashi; S Okuda; T Murai; Y Sato
Journal:  Biochim Biophys Acta       Date:  1987-12-07

3.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

4.  Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines.

Authors:  T Tsuruo; T Oh-hara; H Iida; S Tsukagoshi; Z Sato; I Matsuda; S Iwasaki; S Okuda; F Shimizu; K Sasagawa
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701
  4 in total
  3 in total

1.  Isolation and identification of rhizoxin analogs from Pseudomonas fluorescens Pf-5 by using a genomic mining strategy.

Authors:  Joyce E Loper; Marcella D Henkels; Brenda T Shaffer; Frederick A Valeriote; Harald Gross
Journal:  Appl Environ Microbiol       Date:  2008-03-14       Impact factor: 4.792

Review 2.  Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?

Authors:  Daniele Fanale; Giuseppe Bronte; Francesco Passiglia; Valentina Calò; Marta Castiglia; Florinda Di Piazza; Nadia Barraco; Antonina Cangemi; Maria Teresa Catarella; Lavinia Insalaco; Angela Listì; Rossella Maragliano; Daniela Massihnia; Alessandro Perez; Francesca Toia; Giuseppe Cicero; Viviana Bazan
Journal:  Anal Cell Pathol (Amst)       Date:  2015-09-21       Impact factor: 2.916

3.  Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.

Authors:  A R Hanauske; G Catimel; S Aamdal; W ten Bokkel Huinink; R Paridaens; N Pavlidis; S B Kaye; A te Velde; J Wanders; J Verweij
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.